We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+1.41%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$274M
AUM Growth
+$79.4M
Cap. Flow
+$63.1M
Cap. Flow %
23.07%
Top 10 Hldgs %
74.6%
Holding
47
New
11
Increased
13
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$7.36M
2
VTRS icon
Viatris
VTRS
+$5.82M
3
MDRX
Veradigm Inc. Common Stock
MDRX
+$3.81M
4
RDNT icon
RadNet
RDNT
+$2.42M
5
SNY icon
Sanofi
SNY
+$2.19M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$5.54M
2
ALKS icon
Alkermes
ALKS
+$5.45M
3
LNTH icon
Lantheus
LNTH
+$5.35M
4
PCRX icon
Pacira BioSciences
PCRX
+$3.58M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.86M

Sector Composition

Rank Sector Weight
1 Healthcare 47.9%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$453B
$80.2M 29.32%
250,000
+100,000
+67% +$29.5M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$40.9M 14.96%
100,000
+75,000
+300% +$29.9M
PPA icon
3
CALL
Invesco Aerospace & Defense ETF
PPA
$8.24B
$14.5M 5.29%
+100,000
New +$7.97M
VTRS icon
4
Viatris
VTRS
$20.4B
$14.4M 5.27%
1,500,000
+525,000
+54% +$5.82M
MDRX
5
DELISTED
Veradigm Inc. Common Stock
MDRX
$12.4M 4.53%
950,000
+235,000
+33% +$3.81M
PHR icon
6
Phreesia
PHR
$663M
$10.3M 3.78%
320,000
+35,000
+12% +$1.23M
STRM
7
DELISTED
Streamline Health Solutions
STRM
$8.88M 3.24%
328,725
– –
COLL icon
8
Collegium Pharmaceutical
COLL
$1.15B
$8.52M 3.11%
355,000
-32,000
-8% -$849K
AMGN icon
9
Amgen
AMGN
$208B
$7.25M 2.65%
+30,000
New +$7.36M
CERS icon
10
Cerus
CERS
$433M
$6.68M 2.44%
2,250,000
-250,000
-10% -$753K
THC icon
11
Tenet Healthcare
THC
$20.5B
$5.94M 2.17%
100,000
+5,000
+5% +$278K
TCMD icon
12
Tactile Systems Technology
TCMD
$635M
$5.91M 2.16%
360,000
+105,000
+41% +$1.46M
SIBN icon
13
SI-BONE Inc
SIBN
$788M
$5.41M 1.98%
275,000
-55,000
-17% -$977K
RDNT icon
14
RadNet
RDNT
$5.02B
$5.29M 1.93%
211,500
+111,500
+112% +$2.42M
DCGO icon
15
DocGo
DCGO
$64.3M
$5.28M 1.93%
610,000
+235,000
+63% +$2.07M
SNY icon
16
Sanofi
SNY
$103B
$5.17M 1.89%
95,000
+45,000
+90% +$2.19M
ANGO icon
17
AngioDynamics
ANGO
$611M
$4.91M 1.8%
475,000
-15,000
-3% -$192K
TDOC icon
18
PUT
Teladoc Health
TDOC
$1.22B
$3.88M 1.42%
+150,000
New +$4.01M
INMD icon
19
InMode
INMD
$870M
$3.68M 1.34%
115,000
+25,000
+28% +$856K
THC icon
20
CALL
Tenet Healthcare
THC
$20.5B
$2.97M 1.09%
+50,000
New +$2.78M
RIGL icon
21
Rigel Pharmaceuticals
RIGL
$681M
$2.64M 0.96%
200,000
-30,000
-13% -$477K
IRWD icon
22
Ironwood Pharmaceuticals
IRWD
$696M
$2.21M 0.81%
210,000
+35,000
+20% +$392K
ASND icon
23
Ascendis Pharma A/S
ASND
$16B
$2.14M 0.78%
20,000
-25,000
-56% -$2.86M
ALKS icon
24
Alkermes
ALKS
$8.22B
$2.11M 0.77%
75,000
-200,000
-73% -$5.45M
NEOG icon
25
Neogen
NEOG
$2.63B
$1.85M 0.68%
100,000
-150,000
-60% -$2.82M
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q1 2023 Portfolio in Review

As of Q1 2023, Tamarack Advisers held 47 positions worth $274M, up 41% from $194M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Tamarack Advisers deployed $63.1M of net new capital in Q1 2023, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was Amgen: 30,000 shares worth $7.25M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 69% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Alkermes, an estimated $5.45M trimmed.

  • Tamarack Advisers's largest Q1 2023 buy was Amgen: 30,000 shares worth $7.25M.
  • Tamarack Advisers added most to Viatris in Q1 2023, an estimated $5.82M increase.
  • Tamarack Advisers's biggest Q1 2023 reduction was Alkermes, cutting an estimated $5.45M.
  • Tamarack Advisers fully exited Biogen in Q1 2023, selling an estimated $5.54M.
  • Tamarack Advisers's ten largest holdings make up 75% of its $274M portfolio in Q1 2023.
  • Tamarack Advisers opened 11 new positions and closed 8 in Q1 2023.
  • Tamarack Advisers's portfolio value rose 41% quarter-over-quarter to $274M.

Based on Tamarack Advisers's 13F filing for Q1 2023, filed 11 May 2023.